Thomas Chittenden

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Magnetic Resonance

Diffusion Weighted

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Nimish Gera, Kyle M Fitzgerald, Vijay Ramesh, Purvi Patel, Deepak Kanojia, Federico Colombo, Lena Kien, Simon Aoyama, Lihui Xu, Jussekia Jean, Amit M Deshpande, William C Comb, Thomas Chittenden, Brian P Fiske
MYTX-011: a pH-dependent anti-cMET antibody-drug conjugate designed for enhanced payload delivery to cMET expressing tumor cells. Molecular cancer therapeutics (2024)
Nimish Gera, Kyle M Fitzgerald, Vijay Ramesh, Purvi Patel, Deepak Kanojia, Federico Colombo, Lena Kien, Simon Aoyama, Lihui Xu, Jussekia Jean, Amit M Deshpande, William C Comb, Thomas Chittenden, Brian P Fiske
MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells. Molecular cancer therapeutics (2024)
Juniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, Nicholas C Yoder, Gundo Diedrich, Jennifer G Brown, Jacquelynn Lucas, Megan E Fuller, Thomas Son, Anahita Dastur, Jeff Hooley, Christopher Espelin, Marian Themeles, Francine Z Chen, Ying Li, Michael Chiechi, Jenny Lee, Bhaswati Barat, Lusiana Widjaja, Sergey Gorlatov, James Tamura, Valentina Ciccarone, Olga Ab, Kerry A McEachem, Scott Koenig, Eric H Westin, Paul A Moore, Thomas Chittenden, Richard J Gregory, Ezio Bonvini, Deryk Loo
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Molecular cancer therapeutics 21 (7) (2022)